Gene therapy injection aims to save sight in rare eye disease
NCT ID NCT07161544
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a gene therapy called AAVB-039 for Stargardt disease, an inherited condition that causes vision loss. About 75 adults with a specific gene mutation will receive a single injection under the retina. The main goal is to check safety, but researchers will also measure whether it slows retinal damage and preserves vision.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AAVB-039 (a gene therapy given as a single injection under the retina)
What this could lead to
If it works, this could slow or stop vision loss in people with Stargardt disease, potentially preserving sight for years.
What could go wrong
This is an early (Phase 1/2) trial with only 75 participants, so results may not apply to everyone. Gene therapy under the retina carries risks like inflammation or retinal damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STARGARDT DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Associated Retina Consultants
RECRUITINGPhoenix, Arizona, 85020, United States
Contact
Contact Email: •••••@•••••
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Moorfields Eye Hospital NHS Foundation Trust
RECRUITINGLondon, England, EC1V 2PD, United Kingdom
-
Retina Consultants of Texas
RECRUITINGBellaire, Texas, 77401, United States
Contact
-
Retina Foundation of the Southwest
RECRUITINGDallas, Texas, 75231, United States
Contact
Contact Email: •••••@•••••
-
Retina Vitreous Associates Medical Group
RECRUITINGLos Angeles, California, 90211, United States
Contact
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
The Retina Clinic
RECRUITINGLondon, England, W1G 9AX, United Kingdom
-
University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Email: •••••@•••••
Contact